Viridian Therapeutics Inc

VRDN · NASDAQ

Medical Laboratories · US

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.

Market Data

Price $29.19 -0.46 (-1.55%)

Market Cap$3.03B

P/E Ratio—

EPS$—

52W High$34.29

52W Low$9.90

Beta0.99

Data from Finnhub · Updated Mar 11, 2026